Hemophagocytic Lymphohistiocytosis (HLH) due to EBV Reactivation on Durvalumab: A Case Report

Maury A1*, Corbaux P1, Reverdy T2, Tartas S2, Bonin N3, You B2 and Freyer G2

1Department of Medical Oncology, Hospital Nord, CHU de Saint-Etienne, France
2Department of Medical Oncology, CHU Lyon-Sud, Lyon, France
3Department of Orthopedic Surgery, CHU Lyon-Sud, Lyon, France

^*Correspondance to: Maury Audrey 

 PDF  Full Text Case Report | Open Access

Abstract:

Background: Hemophagocytic lymphohistiocytosis is a serious life-threatening event. It is therefore essential to know how to recognize it and treat it quickly in order to reduce mortality. Methods: This study present a case of a 60-year-old female patient followed in oncology for a recurrent ovarian cancer. She was undergoing a treatment with Durvalumab Bevacizumab, Olaparib and Durvalumab. She subsequently developed fever, dyspnea, anemia and thrombocytopenia, syndrome that was quickly diagnosed as Hemophagocytic Lymphohistiocytosis (HLH). The rapid initiation of treatment with etoposide, dexamethasone and Type G immunoglobulin allowed a normalization of the patient's clinical condition. Discussion: We postulate two causes that could have led to this syndrome: First, the infectious origin by EBV, but also the immunological origin by durvalumab. The rapid initiation of treatment with etoposide, dexamethasone and Type G immunoglobulin allowed a normalization of the patient's clinical condition. It is essential to make people aware of HLH and its causes in order to introduce a curative treatment as soon as possible; our objective being the reduction of its mortality.

Keywords:

Cite the Article:

Maury A, Corbaux P, Reverdy T, Tartas S, Bonin N, You B, et al. Hemophagocytic Lymphohistiocytosis (HLH) due to EBV Reactivation on Durvalumab: A Case Report. Ann Clin Case Rep. 2023; 8: 2387..